{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:52:36Z","timestamp":1791049956139,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02290-1","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:06:25Z","timestamp":1791003985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-activity relationship in [131I]NaI therapy for differentiated thyroid carcinoma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3155-4602","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Luj\u00e1n-Exp\u00f3sito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"10","key":"2290_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","volume":"35","author":"M Luster","year":"2008","unstructured":"Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941\u201359.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2290_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054\u201367.","journal-title":"N Engl J Med"},{"key":"2290_CR3","unstructured":"ECIS \u2013 European Cancer Information System. Data Explorer. 2022. https:\/\/ecis.jrc.ec.europa.eu\/. Accessed 15 Mar 2025."},{"issue":"12","key":"2290_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856\u201383.","journal-title":"Ann Oncol"},{"issue":"1","key":"2290_CR5","first-page":"25","volume":"16","author":"M Mumtaz","year":"2009","unstructured":"Mumtaz M, Lin LS, Hui KC, Mohd Khir AS. Radioiodine I-131 for the therapy of graves\u2019 disease. Malays J Med Sci. 2009;16(1):25\u201333.","journal-title":"Malays J Med Sci"},{"issue":"8","key":"2290_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2967\/jnumed.117.192559","volume":"59","author":"RM Tuttle","year":"2018","unstructured":"Tuttle RM. Controversial issues in thyroid cancer management. J Nucl Med. 2018;59(8):1187\u201394.","journal-title":"J Nucl Med"},{"issue":"8","key":"2290_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2967\/jnumed.117.191338","volume":"59","author":"M Schmidt","year":"2018","unstructured":"Schmidt M, G\u00f6rges R, Drzezga A, Dietlein M. A matter of controversy: Is radioiodine therapy favorable in differentiated thyroid carcinoma? J Nucl Med. 2018;59(8):1195\u2013201.","journal-title":"J Nucl Med"},{"issue":"8","key":"2290_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.2967\/jnumed.118.214197","volume":"59","author":"DA Pryma","year":"2018","unstructured":"Pryma DA. Controversies on the use of radioiodine in thyroid cancer: We need more and better data. J Nucl Med. 2018;59(8):1184\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"2290_CR9","first-page":"195","volume":"38","author":"M Estorch","year":"2019","unstructured":"Estorch M, Mitjavila M, Muros MA, Caballero E. en nombre del Grupo de Trabajo de Endocrinolog\u00eda de la SEMNIM. Tratamiento del c\u00e1ncer diferenciado de tiroides con radioyodo a la luz de las gu\u00edas y de la literatura cient\u00edfica. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019;38(3):195\u2013203.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"issue":"10","key":"2290_CR10","first-page":"1587","volume":"47","author":"RM Tuttle","year":"2006","unstructured":"Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47(10):1587\u201391.","journal-title":"J Nucl Med"},{"issue":"1","key":"2290_CR11","first-page":"35","volume":"11","author":"MA Ruiz","year":"2010","unstructured":"Ruiz MA, Ferrer N, C\u00f3rdoba D, Alonso L, Sastre JM, Arranz L. Dosimetr\u00eda de pacientes con c\u00e1ncer diferenciado de tiroides en tratamiento de terapia metab\u00f3lica con I-131 a partir de medidas de tasa de dosis externa. Rev Fis Med. 2010;11(1):35\u201342.","journal-title":"Rev Fis Med"},{"issue":"3","key":"2290_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med"},{"issue":"11","key":"2290_CR13","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00259-023-06295-0","volume":"50","author":"J Taprogge","year":"2023","unstructured":"Taprogge J, Vergara-Gil A, Leek F, Abreu C, V\u00e1vrov\u00e1 L, Carnegie-Peake L, et al. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023;50(11):3225\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2290_CR14","doi-asserted-by":"publisher","first-page":"6423","DOI":"10.1002\/mp.17182","volume":"51","author":"MA Contardi","year":"2024","unstructured":"Contardi MA, Nam\u00edas M, Cragnolino G, Arro\u00f1ada GD, Cragnolino DE. A strategy for estimating radiation dose to the blood in outpatient settings in differentiated thyroid cancer therapy with 131I-NaI. Med Phys. 2024;51(9):6423\u201331.","journal-title":"Med Phys"},{"issue":"4","key":"2290_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1053\/j.semnuclmed.2024.05.002","volume":"54","author":"NC Nguyen","year":"2024","unstructured":"Nguyen NC, Anigati EM, Desai NB, \u00d6z OK. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies. Semin Nucl Med. 2024;54(4):488\u201396.","journal-title":"Semin Nucl Med"},{"issue":"7","key":"2290_CR16","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3390\/diagnostics12071763","volume":"12","author":"M Pacilio","year":"2022","unstructured":"Pacilio M, Conte M, Frantellizzi V, De Feo MS, Pisani AR, Marongiu A, et al. Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer. Diagnostics (Basel). 2022;12(7):1763.","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"2290_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s12149-025-02042-7","volume":"39","author":"AJ Al Jabri","year":"2025","unstructured":"Al Jabri AJ, Cooke J, Cournane S, Healy ML. Blood and bone marrow dosimetry for thyroid cancer patients prepared with rhTSH injection. Ann Nucl Med. 2025;39(7):676\u201386.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"2290_CR18","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s00259-023-06240-1","volume":"50","author":"A Mauguen","year":"2023","unstructured":"Mauguen A, Grewal RK, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, et al. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2023;50(10):2971\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2290_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/cimb48040362","volume":"48","author":"VD Rokashkov","year":"2026","unstructured":"Rokashkov VD, Spirina LV, Tarasenko NV, Chizhevskaya SY. Molecular Mechanisms of Radioiodine Refractoriness in Differentiated Thyroid Cancer: Focus on Sodium\/Iodide Symporter Dysregulation. Curr Issues Mol Biol. 2026;48(4):362.","journal-title":"Curr Issues Mol Biol"},{"issue":"6","key":"2290_CR20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G, EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2290_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/genes12020126","volume":"12","author":"SN Silva","year":"2021","unstructured":"Silva SN. Special issue: Genetic perspectives in thyroid cancer. Genes (Basel). 2021;12(2):126.","journal-title":"Genes (Basel)"},{"issue":"1","key":"2290_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clon.2022.07.002","volume":"35","author":"J Wadsley","year":"2023","unstructured":"Wadsley J, Armstrong N, Bassett-Smith V, Beasley M, Chandler R, Cluny L, et al. Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer in the UK. Clin Oncol (R Coll Radiol). 2023;35(1):42\u201356.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2290_CR23","unstructured":"Consejo de Seguridad Nuclear. Sociedad Espa\u00f1ola de F\u00edsica M\u00e9dica, Sociedad Espa\u00f1ola de Protecci\u00f3n Radiol\u00f3gica. Criterios de alta de pacientes y medidas para la protecci\u00f3n radiol\u00f3gica del p\u00fablico despu\u00e9s de tratamientos metab\u00f3licos con I-131. Foro sobre Protecci\u00f3n Radiol\u00f3gica en el Medio Sanitario; 2011."}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02290-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:01:52Z","timestamp":1791046912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02290-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":23,"alternative-id":["2290"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02290-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}